Skip to main content
Investor Relations Contact Us Careers
Nasdaq: FEMY
FemBloc is approved in Europe and select countries outside the U.S. and is currently enrolling in a U.S. trial for FDA approval.
Non-Surgical Permanent Birth Control

Women deserve more than invasive surgery.

As concerns about unintended pregnancy and long-term hormonal contraceptive use increase, there is a growing need for a safer, in-office permanent solution delivered by OB/GYNs.

Learn about FemBloc FINALE Trial →
OB/GYN consulting a patient in an exam room
The Challenge

Permanent birth control is too often limited by procedural risk.

Millions of women remain on the sidelines, continuing temporary birth control despite the risks, to avoid surgery.

~13M
women in the U.S. no longer intend children7,8
~90%
stay on temporary birth control to avoid surgery8,9
~1.2M
elect surgical sterilization each year8,10
  1. 7. Jones et al. Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995. National health statistics reports; no 60. Hyattsville, MD: National Center for Health Statistics. 2012.
  2. 8. Daniels et al. Current contraceptive status among women aged 15–49: United States, 2017–2019. NCHS Data Brief, no 388. Hyattsville, MD: National Center for Health Statistics. 2020.
  3. 9. National health statistics reports; no 60. Hyattsville, MD: National Center for Health Statistics. 2012.
  4. 10. Martinez GM. Receipt of family planning services in the United States: 2022–2023. NCHS Data Brief, no 520. Hyattsville, MD: National Center for Health Statistics. 2024. DOI: https://dx.doi.org/10.15620/cdc/169629
Our Solution: Treatment FemBloc.com →

Treat safely in OB/GYNs
office with FemBloc system.

Treatment that works with the body’s natural response and enables women to pursue permanent birth control sooner without surgery in their OB/GYNs office.

  • Performed in-office
  • Creates natural scar tissue within a small section of each fallopian tube to permanently block pathway
  • Simple transcervical procedure
  • No surgery, anesthesia, or incisions, as required with traditional sterilization
  • No hormones, unlike temporary or reversible birth control methods
FemBloc is approved in Europe and select countries outside the U.S. and is currently enrolling in a U.S. trial for FDA approval.
U.S. Clinical Trial

The FINALE trial is in
the final step toward U.S. approval.

The FINALE trial is Femasys’ U.S. pivotal study evaluating FemBloc® for permanent birth control. If you are a patient interested in participating, or a physician interested in becoming an investigational site, learn more below.

Interested in Participating?
FemBloc.com →
Interested in becoming a Study site?
FemBloc.com/investigator →
FINALE trial site locations Find a study location